Diagnosis and management of chronic myelomonocytic leukemia

Current Hematologic Malignancy Reports

Volumn 3, Issue 1, 2008, Pages 31-36

  Onida, Francesco ^a   Beran, Miloslav ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 9 NITRO CAMPTOTHECIN; AZACITIDINE; BENDAMUSTINE; BUSULFAN; CAMPTOTHECIN DERIVATIVE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; HYDROXYUREA; IMATINIB; LONAFARNIB; MERCAPTOPURINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RELAPSE; CANCER SCREENING; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; PATIENT CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 41849134682     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0006-x     Document Type: Review

References (42)

1. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
2. Vardiman JW, Harris NL, Brunning RD, et al.: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
3. Onida F, Beran M: Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 2004, 3:218-226.
4. Bennett JM, Catovsky D, Daniel MT, et al.: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994, 87:746-754.
5. Greenberg P, Cox C, Le Beau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
6. Voglová J, Chrobák L, Neuwirtová R, et al.: Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia - distinct subgroups or two stages of the same disease? Leuk Res 2001, 25:493-499.
7. Vallespí T, Blanco A, Sánchez-Morata C, et al.: Proliferative chronic myelomonocytic leukemia (P-CMML) emerging after splenectomy in two patients with dysplastic CMML (D-CMML) [abstract]. Leuk Res 1997; 21(Suppl 1):S8.
8. Onida F, Kantarjian H, Ball G, et al.: The dysplastic versus proliferative classification dilemma of chronic myelomonocytic leukemia: a retrospective single institution analysis of 273 patients [abstract]. Blood 2001, 98(Suppl 1):2607. Abstract 622a.
9. Worsley A, Oscier DG, Stevens J, et al.: Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988, 68:17-21.
10. Aul C, Gattermann N, Heyll A, et al.: Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992, 6:52-59.
11. Onida F, Kantarjian HM, Smith TL, et al.: Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002, 99:840-849.
12. Germing U, Strupp C, Aivado M, et al.: New prognostic parameters for chronic myelomonocytic leukemia. Blood 2002, 100:731-732.
13. Germing U, Kundgen A, Gattermann N: Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004, 45:1311-1318.
14. Beran M, Wen S, Shen Y, et al.: Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007, 48:1150-1160. Following the proposal for a CMML-specific prognostic scoring system (MDAPS), which was based on a retrospective analysis of 213 patients, the authors validated it prospectively on a cohort of 250 new patients with CMML.
15. Golub TR, Barker GF, Lovett M, et al.: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
16. Ross TS, Bernard OA, Berger R, et al.: Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998, 91:4419-4426.
17. Schwaller J, Anastasiadou E, Cain D, et al.: H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 2001, 97:3910-3918.
18. Magnusson MK, Meade KE, Brown KE, et al.: Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001, 98:2518-2525.
19. Jelinek J, Oki Y, Gharibyan V, et al.: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in LMMC, Philadelphia chromosome-negative LMC, and megakaryocytic leukemia. Blood 2005, 106:3370-3373. This paper reported the results of the JAK2 mutational screening performed on the largest series of patients with CMML (n = 52) ever analyzed for the presence of such abnormality.
20. Levine RL, Pardanani A, Tefferi A, et al.: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673-683. A comprehensive review of the role of the JAK2 V617F mutation in MPDs with regard to pathogenesis and therapy as well as an update on the ongoing development of JAK2 inhibitors.
21. Kerridge I, Spencer A, Azzi A, et al.: Response to erythropoietin in chronic myelomonocytic leukaemia. Intern Med J 2001, 31:371-372.
22. Giraldo P, Nomdedeu B, Loscertales J, et al.: Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006, 107:2807-2816.
23. Arshad M, Seiter K, Bilaniuk J, et al.: Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005, 23:8533-8534.
24. Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
25. Drechsler M, Hildebrandt B, Kündgen A, et al.: Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol 2007, 86:353-354.
26. Wattel E, Guerci A, Hecquet B, et al.: A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996, 88:2480-2487.
27. Beran M, Kantarjian H, O'Brien S, et al.: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996, 88:2473-2479.
28. Quintas-Cardama A, Kantarjian H, O'Brien S, et al.: Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 2006, 107:1525-1529.
29. Strupp C, Knipp S, Hartmann J, et al.: A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma 2007, 48:1161-1166.
30. Platzbecker U, Mohr B, von Bonin M, et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 2007, 21:2384-2385.
31. Beran M, Estey E, O'Brien S, et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999, 17:2819-2830.
32. Beran M, Onida M, Cortes J, et al.: Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia [abstract]. Blood 2001, 98:624a.
33. Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
34. Kaminskas E, Farrell A, Abraham S, et al.: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005, 11:3604-3608. This paper summarized data submitted to the FDA for marketing approval of 5-azacitidine for treatment of patients with MDS.
35. Wijermans P, Lubbert M, Verhoef G, et al.: Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000, 18:956-962.
36. Kantarjian H, Oki Y, Garcia-Manero G, et al.: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57. This randomized study confirmed the low toxicity profile and the good anti-MDS and anti-CMML activities of decitabine, selecting the schedule with the highest dose intensity as the best for epigenetic modulation and clinical responses.
37. Kurzrock R, Sebti SM, Kantarjian HM, et al.: Phase I study of a farnesyltransferase inhibitor, R115777, in patients with myelodysplastic syndrome [abstract]. Blood 2001, 98:623a.
38. Kurzrock R, Fenaux P, Raza A, et al.: High risk myelodysplastic syndrome (MDS): first result of international phase 2 study with oral farnesyl transferase inhibitor R22577 (Zarnestra™) [abstract]. Blood 2004, 104:68a.
39. Feldman E, Cortes J, Holyoake T, et al.: Continuous oral Lonafarnib (SarasarTM) for the treatment of patients with myelodysplastic syndrome [abstract]. Blood 2003, 102:421a.
40. Kerbauy DM, Chyou F, Gooley T, et al.: Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005, 11:713-720. This paper reported the outcomes in 43 patients with CMML (children and adults) who consecutively underwent allogeneic hematopoietic SCT in a 15-year period at Fred Hutchinson Cancer Research Center in Seattle.
41. Kroger N, Zabelina T, Guardiola P, et al.: Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002, 118:67-73.
42. Elliott MA, Tefferi A, Hogan WJ, et al.: Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006, 37:1003-1008. This paper reported the outcomes in 17 adults patients with CMML who consecutively underwent allogeneic hematopoietic SCT in a 13-year period at the Mayo Clinic in Rochester, Minnesota.